Journal article
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
- Abstract:
-
In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Publisher:
- Elsevier
- Journal:
- Leukemia research
- Volume:
- 38
- Issue:
- 12
- Pages:
- 1381-1391
- Publication date:
- 2014-09-01
- DOI:
- EISSN:
-
1873-5835
- ISSN:
-
0145-2126
- Source identifiers:
-
493462
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:493462
- UUID:
-
uuid:330a88d2-069a-4497-999c-97100ab85d74
- Local pid:
- pubs:493462
- Deposit date:
- 2015-01-06
Terms of use
- Copyright date:
- 2014
If you are the owner of this record, you can report an update to it here: Report update to this record